A comprehensive introduction to Vepotolizumab/Urova

Polatuzumab/Polatuzumab is an antibody-drug conjugate (ADC) developed by Roche. It was approved by the US FDA for the first time in June 2019 for the treatment of relapsed or refractory diffuse large B-cell lymphoma. The development concept of this drug stems from precision medicine: it uses monoclonal antibodies against CD79b to identify tumor cells, and then delivers the cytotoxic molecule MMAE into the cancer cells through chemical linkers, ultimately inducing cell death. This mechanism of action takes into account both targeting and lethality, reducing non-specific damage to normal cells.

In terms of clinical application, the combination of velpotuzumab combined with rituximab and bendamustine has become an important treatment option for relapsed and refractory DLBCL (non-Hodgkin lymphoma) . Its efficacy and tolerability have been verified in overseas studies, providing new hope for patients who have failed traditional chemotherapy. With the official launch of vepotuzumab in China in 2022 and its rapid inclusion in the medical insurance directory, the drug has gradually entered domestic clinical practice. For patients, this not only means the opportunity to obtain internationally advanced treatments, but also represents a reduction in actual economic burden.

In terms of price and market conditions, vepotuzumab currently only has the original version, with a specification of 30 mg/bottle. The domestic price before medical insurance is about 10,000 yuan, and the patient payment ratio has dropped significantly after medical insurance negotiations. The overseas price is higher, about US$3,900 per bottle. Although the current indications are relatively concentrated, with continued exploration in the field of hematology, attention is being paid to its application potential in other B-cell lymphomas.

Overall, vepotuzumab is a major advancement in the field of lymphoma treatment in recent years. Its emergence not only supplements the shortcomings of traditional treatments, but also marks the gradual establishment of the position of antibody-conjugated drugs in hematological tumors. As more real-world data accumulate, the therapeutic value and long-term impact of vepotuzumab will become clearer.

Reference materials:https://www.drugs.com/polivy.html